SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 54.74+4.1%Jan 21 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: software salesperson who wrote (5766)2/27/2002 11:16:28 PM
From: Biomaven  Read Replies (2) of 52153
 
sales,

Interesting points.

Do you know what the numbers breakdown is between pure P and PA?

We still don't know what the long-term tox issues with Enbrel/Remicade are. I wouldn't be at all surprised to see some new issues crop up with long term treatment. (Of course the same can be said for the new biologics).

Part of the issue with mtx is that many patients refuse the liver biopsies that they are supposed to have. Here's a comment from a doctor responding to another doctor whose patient refused the biopsy:

Unfortunately, the dilemma concerning what to do when a patient refuses liver biopsy is one that is common in all practices that use MTX. We are truly between the " devil and the deep blue sea ", and coming from a state in which the surfeit of attorneys approaches the absurd, I would probably vote to stop the MTX despite whatever you find out about blood tests. Believe me, the patient will not remember any of your warnings when her attorney serves you with papers. Another approach would be to refer her to the nearest medical center where they can take the responsibility. I know that some of you feel differently, and that the patient may suffer in this scenario. So be it. We didn't create the system.

Speaking of mtx, I was quite surprised to see that the SCIO p38 RA trial announced today is a combo trial with mtx. I don't understand their reasoning, but I doubt it can be good news. (Note that the abandoned VRTX effort that showed efficacy in an oral P38 inhibitor was a monotherapy trial.)

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News